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Protein-tyrosine phosphatase (PTP)-PEST is a cyto-
plasmic tyrosine phosphatase that can bind and dephos-
phorylate the focal adhesion-associated proteins
p130CAS and paxillin. Focal adhesion kinase (FAK) and
cell adhesion kinase b (CAKb)/PYK2/CADTK/RAFTK are
protein-tyrosine kinases that can colocalize with, bind
to, and induce tyrosine phosphorylation of p130CAS and
paxillin. Thus, we considered the possibility that these
kinases might be substrates for PTP-PEST. Using a com-
bination of substrate-trapping assays and overexpres-
sion of PTP-PEST in mammalian cells, CAKb was found
to be a substrate for PTP-PEST. Both the major auto-
phosphorylation site of CAKb (Tyr402) and activation
loop tyrosine residues, Tyr579 and Tyr580, were targeted
for dephosphorylation by PTP-PEST. Dephosphoryl-
ation of CAKb by PTP-PEST dramatically inhibited
CAKb kinase activity. In contrast, FAK was a poor sub-
strate for PTP-PEST, and treatment with PTP-PEST had
no effect on FAK kinase activity. Tyrosine phosphoryla-
tion of paxillin, which is greatly enhanced by CAKb
overexpression, was dramatically reduced upon coex-
pression of PTP-PEST. Finally, endogenous PTP-PEST
and endogenous CAKb were found to localize to similar
cellular compartments in epithelial and smooth muscle
cells. These results suggest that CAKb is a substrate of
PTP-PEST and that FAK is a poor PTP-PEST substrate.
Further, PTP-PEST can negatively regulate CAKb sig-
naling by inhibiting the catalytic activity of the kinase.
Tyrosine phosphorylation is a post-translational modifica-
tion that is essential for many signal transduction cascades,
including growth factor receptor and focal adhesion signaling.
Cellular phosphotyrosyl levels are kept in homeostasis by the
competing action of two classes of enzymes, protein-tyrosine
kinases (PTKs)1 and protein-tyrosine phosphatases (PTPs).
There is a vast literature describing the role of PTKs in the
regulation of signal transduction. As more PTPs are being
discovered, it has become apparent that these proteins, like
PTKs, play an integral role in regulating cellular signaling
pathways.
PTP-PEST is one of a number of cytoplasmic phosphatases
characterized by the presence of several PEST-rich regions
(1–4), motifs that have been found in many proteins that are
rapidly degraded in the cell (5). PTP-PEST, however, appears
to be quite stable (6). Structurally, it is composed of an N-
terminal catalytic domain and a C-terminal tail containing five
proline-rich regions, several of which constitute consensus Src
homology 3 binding sites. Indeed, PTP-PEST binds the adaptor
protein Grb2 and the tyrosine kinase Csk in an Src homology
3-dependent manner (7, 8). PTP-PEST also binds the adaptor
protein Shc via a phosphotyrosine binding domain-mediated
interaction. However, this interaction occurs in a non-phospho-
tyrosine-dependent manner through an NPLH sequence in the
C-terminal tail of PTP-PEST (9). Although PTP-PEST has been
shown to associate with these signaling molecules, its role in
regulation of these signaling pathways remains to be fully
elucidated. Grb2 binding was reported to bring PTP-PEST into
association with activated epidermal growth factor receptor;
however, the epidermal growth factor receptor does not appear
to be a substrate (7). An alternative hypothesis is that PTP-
PEST may instead regulate epidermal growth factor receptor
signaling by dephosphorylating receptor substrates. Csk was
recently shown to cooperate with the tyrosine phosphatase
PEP, a structural homologue of PTP-PEST, in inhibiting T-cell
antigen receptor signaling (10). PEP could dephosphorylate
and inactivate PTKs responsible for T-cell activation but only
when associated with Csk. A role for PTP-PEST in Csk signal-
ing events has yet to be established. The Shc proteins are
adaptor molecules most closely linked with activation of the
Ras pathway (11, 12). Interestingly, Shc is phosphorylated on
tyrosine itself (11). PTP-PEST, however, has not been impli-
cated in regulation of the Ras signaling pathway, and Shc has
not been identified as a substrate. In addition to binding these
signaling molecules, the C-terminal domain of PTP-PEST has
docking sites for two known substrates. p130CAS binds PTP-
PEST in an Src homology 3-dependent manner (13), and pax-
illin binds through its two C-terminal LIM domains to two
nonoverlapping stretches of a 52-amino acid sequence in PTP-
PEST (14, 15). Both p130CAS and paxillin are substrates for
PTP-PEST, and their association with the C-terminal domain
of PTP-PEST is required for dephosphorylation of these sub-
strates in vivo (13, 15, 16).
Paxillin and p130CAS localize to focal adhesions and undergo
rapid tyrosine phosphorylation upon cell adhesion (17). Paxillin
and p130CAS also become tyrosine-phosphorylated in response
to various physiological stimulants including bombesin, plate-
let-derived growth factor, nerve growth factor, and angiotensin
II (18, 19). Both proteins act as adaptor molecules in integrin
signaling. Paxillin binds to several focal adhesion-associated
proteins including vinculin, FAK, and c-Src (19). Integrin-me-
diated tyrosine phosphorylation of paxillin creates binding
sites for the SH2 domains of Crk and Csk (20, 19). Tyrosine
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phosphorylation of paxillin has been implicated in the control
of biological events such as cell spreading (21), cell adhesion
(22), and cell motility (23, 24). Tyrosine phosphorylation of
p130CAS also creates docking sites for the SH2 domain of Crk
(25). The p130CAS-Crk complex has been proposed to regulate
cell migration (26), and p130CAS is thought to act as a mediator
for FAK-promoted cell migration (27). PTP-PEST has been
implicated in the regulation of cell motility (28, 29) and may do
so by targeting paxillin and/or p130CAS for dephosphorylation.
Paxillin and p130CAS are potential substrates for several
candidate tyrosine kinases including FAK and CAKb. Paxillin
and p130CAS can directly bind to FAK and CAKb and become
tyrosine-phosphorylated in response to stimuli that activate
these PTKs (17). FAK and CAKb are structurally related cyto-
plasmic tyrosine kinases composed of a central catalytic do-
main flanked by N- and C-terminal noncatalytic domains (30).
Although structurally similar and able to associate with many
of the same proteins, it is unclear whether these kinases share
similar functions. While FAK has been most strongly implicated
as a major component of integrin-mediated signaling pathways
(17), there have been conflicting reports as to whether CAKb is
regulated by integrin mediated cell adhesion (31–33). Unlike
FAK, CAKb is regulated by stimuli that induce changes in intra-
cellular Ca21 (30). Like other PTKs, tyrosine phosphorylation of
FAK and CAKb plays an important role in regulating signaling.
FAK and CAKb share four conserved sites of tyrosine phospho-
rylation. They are the Src-family SH2 domain binding site at
Tyr397 in FAK and Tyr402 in CAKb, the Grb2-SH2 domain bind-
ing site at Tyr925 in FAK and Tyr881 in CAKb, and two regulatory
sites in the activation loop of the kinase domains: Tyr576/577 in
FAK and Tyr579/580 in CAKb (30, 34).
FAK and CAKb are particularly good candidate PTP-PEST
substrates, since these kinases both bind paxillin and p130CAS
(35), two previously identified substrates (15, 16). Two lines of
evidence suggest that FAK may be a substrate. First, PTP-
PEST activity was coimmunoprecipitated with FAK (36), al-
though this association is indirect and appears to be mediated
by paxillin. Second, PTP-PEST2/2 cells exhibited not only in-
creased paxillin and p130CAS phosphotyrosine but also in-
creased tyrosine phosphorylation of FAK (29). These results
suggest that FAK may be a substrate of PTP-PEST and that
PTP-PEST may regulate signaling both at the level of the
kinase and the substrate. On the other hand, PTP-PEST may
not play a major role in FAK dephosphorylation, since the two
proteins fail to colocalize intracellularly.2 Alternatively, PTP-
PEST may regulate CAKb signaling. In this report, we explore
the hypothesis that FAK and CAKb may be PTP-PEST sub-
strates. We identify CAKb as a specific substrate of PTP-PEST
using a substrate-trapping approach and by demonstrating
dephosphorylation of CAKb by PTP-PEST in vivo. In contrast,
PTP-PEST bound very weakly to FAK in a substrate-trapping
assay and was a weaker substrate for dephosphorylation than
CAKb. We determined that PTP-PEST could target the major
autophosphorylation site of CAKb as well as one or both ty-
rosines in the activation loop of the catalytic domain. We dem-
onstrate that PTP-PEST is able to inhibit CAKb kinase activity
both in vitro and in vivo. Finally, endogenous PTP-PEST and
endogenous CAKb were shown to reside in similar cellular
compartments within GN4 and A7r5 cells. These results sug-
gest that PTP-PEST can inhibit CAKb signaling by impairing
the activity of the kinase and by dephosphorylating down-
stream substrates.
EXPERIMENTAL PROCEDURES
Cells—HEK 293 cells were maintained in Dulbecco’s modified Ea-
gle’s medium/Ham’s F-12 medium supplemented with 10% fetal bovine
serum and A7r5 vascular smooth muscle cells in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum. GN4 cells
were obtained from Dr. H. Shelton Earp and were maintained in Rich-
ter’s minimal essential medium supplemented with 10% fetal bovine
serum. Cells were transfected using LipofectAMINE (Life Technologies,
Inc.) according to the manufacturer’s recommended protocol.
Molecular Biology—The epitope-tagged (KT3) wild type, dl367–400,
dl297–493, and P337A PTP-PEST constructs have been described pre-
viously (15, 36). To construct pcDNA 3.1-FAK, the FAK cDNA was
excised from pBS-FAK (37) using XbaI and SalI, which cut in the
multiple cloning site flanking the FAK insert. The FAK-containing
fragment was inserted between the NheI and XhoI sites of pcDNA3.1.
Wild type and CAKb YF mutants were kindly provided by Drs. Xiong Li
and H. Shelton Earp (University of North Carolina) and have been
described previously (34). For expression as a glutathione S-transferase
(GST) fusion protein, a fragment of the PTP-PEST cDNA encoding the
catalytic domain (amino acids 1–301) was amplified by polymerase
chain reaction and subcloned into pGEX2TK (Amersham Pharmacia
Biotech) in frame with the GST coding sequence. The C231S PTP-PEST
substrate-trapping mutant (GST/PTP-PESTC231S) was generously pro-
vided by Dr. André Veillette (McGill University). This mutant encodes
amino acids 1–301 with cysteine 231 mutated to serine. GST-paxill-
inN-C3 was generated by amplifying a fragment of the paxillin cDNA
(encoding amino acids 1–312) by polymerase chain reaction using prim-
ers that created a BamHI site at the 59-end and an EcoRI site at the
39-end. The fragment was subcloned into pGEX2TK in frame with the
GST coding sequence. The fusion proteins were expressed by incubation
with 0.3 mM isopropyl b-D-thiogalactopyranoside for 5 h at 30 °C, the
bacteria were lysed by sonication, and the fusion proteins were purified
using glutathione-agarose beads (Sigma) (38).
Protein Analysis—Cells were lysed in modified radioimmune precip-
itation assay buffer (36), and protein concentrations were determined
using the BCA assay (Pierce). Immunoprecipitations were performed
using ;500 mg of cell lysate and 10 ml of polyclonal antisera or 2 mg of
purified antibody. For CAKb immunoprecipitations, a polyclonal anti-
serum was used (described below). Paxillin was immunoprecipitated
using a polyclonal antiserum described previously (39), and FAK was
immunoprecipitated using the BC4 polyclonal antiserum (37), a gift of
Dr. Thomas Parsons (University of Virginia). The immune complexes
were recovered by incubation with protein A-Sepharose beads (Amer-
sham Pharmacia Biotech) for 1–2 h at 4 °C. Immune complexes were
washed twice with lysis buffer and twice with Tris-buffered saline (10
mM Tris-HCl (pH 7.5), 150 mM NaCl). The samples were boiled in
Laemmli sample buffer (40) and analyzed by SDS-PAGE and Western
blotting (41). For Western blotting, monoclonal antibodies recognizing
CAKb, paxillin, and the RC20 phosphotyrosine antibody were pur-
chased from BD Transduction Laboratories (Lexington, KY). The FAK
2A7 monoclonal antibody was kindly provided by Dr. Thomas Parsons
(University of Virginia). A rabbit polyclonal antiserum recognizing the
noncatalytic domain of PTP-PEST has been described previously (15).
CAKb phosphorylation site-specific antibodies (PY402, PY579, and
PY579/580) were obtained from BIOSOURCE International (Camarillo,
CA). These affinity-purified (using both negative and positive affinity
purification methods) rabbit polyclonal antibodies have been shown to
be highly selective for the targeted phosphorylation site by analyzing
site-directed (YF) mutants at the phosphorylation site of interest (see
Fig. 5). For RC20 phosphotyrosine immunoblots, membranes were
blocked in Tris-buffered saline (10 mM Tris-HCl (pH 7.5), 150 mM NaCl),
supplemented with 0.1% Tween 20 (Sigma). For CAKb phosphospecific
antibodies, immunoblots were blocked in Tris-buffered saline, supple-
mented with 0.1% Tween 20 (Sigma) and 2% fish gelatin (Sigma).
Immunoblots were incubated with 0.5 mg/ml phosphospecific antibody
for 1 h at room temperature, washed, and incubated with horseradish
peroxidase-conjugated protein A (Amersham Pharmacia Biotech). En-
hanced chemiluminescence (Amersham Pharmacia Biotech) was used
for detection of proteins.
Generation of CAKb Polyclonal Antiserum—The rat CAKb cDNA
was used to generate a GST fusion protein containing amino acids
226–306. These residues were amplified by polymerase chain reaction
and subcloned into pGEX2TK in-frame with the GST coding sequence.
This fusion protein was gel-purified and used as an antigen to prepare
polyvalent rabbit antiserum as described previously (37). For primary
immunizations, 1 mg of fusion protein in phosphate-buffered saline was
emulsified with complete Freund’s adjuvant and injected subcutane-
2 P. D. Lyons, J. M. Dunty, E. M. Schaefer, and M. D. Schaller,
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ously into female New Zealand White rabbits. For all boosts, 500 mg of
antigen in phosphate-buffered saline was emulsified with Freund’s
incomplete adjuvant and injected subcutaneously. Serum was prepared
by centrifugation of cellular and clotted material from whole blood.
Substrate-trapping Assay—Cells were treated with pervanadate and
lysed as described previously (16). Briefly, confluent cells were treated
with 50 mM pervanadate for 30 min and lysed in radioimmune precip-
itation assay buffer supplemented with 5 mM iodoacetic acid for 30 min
at 4 °C. After lysis, 10 mM dithiothreitol was added to inactivate any
unreacted iodoacetic acid. Pervanadate-treated cell lysates (500 mg)
were precleared with 10 mg of GST bound to glutathione-agarose beads
at 4 °C for 1 h. The cleared supernatants were then incubated with 5 mg
of either GST alone, GST/PTP-PESTWT, or GST/PTP-PESTC231S fusion
protein immobilized on glutathione-agarose beads at 4 °C for 1 h. The
beads were washed as described for immune complexes above, and
bound protein was detected by Western blotting.
In Vitro Kinase Assay—CAKb and FAK were immunoprecipitated
using polyclonal antiserum as described above. Immune complexes
were washed twice in lysis buffer and twice in kinase reaction buffer (50
mM Tris-HCl (pH 7.4), 5 mM MnCl2, 5 mM MgCl2) and then resuspended
in 20 ml of kinase reaction buffer supplemented with 20 mM cold ATP, 10
mCi of [g-32P]ATP (6000 Ci/mol; PerkinElmer Life Sciences), and 5 mg of
GST-paxillinN-C3 as an exogenous substrate. The reaction was stopped
by the addition of Laemmli sample buffer after incubation at room
temperature for 10 min. Samples were resolved by SDS-PAGE and
analyzed by autoradiography. In some experiments, pervanadate-
treated lysates (500–1000 mg) were incubated with GST/PTP-PESTWT
(1–4 mg) immobilized on glutathione beads for up to 20 min at room
temperature or 1 h on ice. The phosphatase was removed by centrifu-
gation, vanadate was added to the sample, and CAKb or FAK was
immunoprecipitated. The immune complexes were analyzed in the in
vitro kinase assay or by Western blotting.
Immunofluorescence—Cells were fixed in 3.7% formaldehyde and
permeabilized with 0.5% Triton X-100 as previously described (42).
Commercially available monoclonal antibodies directed against PTP-
PEST (Exalpha Biologicals Inc., Boston MA) and CAKb (BD Transduc-
tion Laboratories) were used. A secondary rabbit anti-mouse bridging
antibody and tertiary donkey anti-rabbit antibody conjugated to fluo-
rescein (Jackson Immunoresearch Laboratories Inc., West Grove PA)
were used to detect the primary antibody. The cells were visualized
using a Leitz Orthoplan microscope, and images were collected with a
Hamamatsu CCD camera and MetaMorph imaging software (Universal
Imaging Corp., West Chester, PA).
RESULTS
PTP-PEST Substrate Traps CAKb—The hypothesis that
FAK and CAKb are PTP-PEST substrates was initially tested
using an in vitro substrate-trapping assay. FAK and CAKb
were overexpressed in HEK 293 cells, and the cells were
treated with pervanadate to increase the cellular pool of ty-
rosine-phosphorylated proteins. Cell lysates were prepared and
incubated with GST fusion proteins containing the catalytic
domains of either wild type PTP-PEST (GST/PTP-PESTWT) or
the catalytically inactive, substrate-trapping mutant, GST/
PTP-PESTC231S. As shown in Fig. 1A, CAKb bound to GST/
PTP-PESTC231S (lane 3) but was unable to bind GST/PTP-
PESTWT or GST alone (lanes 1 and 2). Upon overexposure of
the blot, however, a very small amount of CAKb was observed
to bind to GST/PTP-PESTWT (data not shown), implying that
there may be a weak interaction between CAKb and an uni-
dentified site in the PTP-PEST catalytic domain. CAKb from
lysates of cells not stimulated with pervanadate failed to bind
to GST/PTP-PESTC231S (data not shown; see Fig. 4A). These
two results suggest that the observed phosphotyrosine depend-
ent interaction of CAKb with GST/PTP-PESTC231S was due to
substrate binding to the active site of the phosphatase.
Whereas CAKb was readily detectable in complex with GST/
PTP-PESTC231S (Fig. 1A, lane 3), no detectable FAK was bound
(Fig. 1B, lane 3). FAK could very weakly bind to the GST/PTP-
PESTC231S fusion protein as seen upon overexposure of the
Western blot (data not shown). Note that the signal intensities
of the loading controls for the FAK blot (Fig. 1B, lane 4) and
CAKb blot (Fig. 1A, lane 4) are similar. These data suggest that
CAKb is a preferred substrate for PTP-PEST in comparison
with FAK. In order to examine the ability of PTP-PEST to
substrate trap endogenous CAKb, the A7r5 vascular smooth
muscle cell line was employed. Cells were treated with per-
vanadate, and lysates were prepared. CAKb from these lysates
bound to GST/PTP-PESTC231S but was unable to bind GST/
PTP-PESTWT or GST alone (Fig. 1C, lanes 1–3). CAKb from
cells not treated with pervanadate also failed to bind to any of
the fusion proteins (data not shown). These results suggest
that CAKb was being trapped by the catalytically inactive
mutant, GST/PTP-PESTC231S, and is likely a substrate for
PTP-PEST.
PTP-PEST Dephosphorylates CAKb in Vivo—Next, the abil-
ity of PTP-PEST to dephosphorylate CAKb in vivo was exam-
ined. CAKb was expressed either alone or with PTP-PEST in
HEK 293 cells. The cells were then lysed, and CAKb was
immunoprecipitated and Western blotted for phosphotyrosine.
As shown in Fig. 2A, CAKb was phosphorylated on tyrosine
when expressed alone (top panel, lane 1) but was dramatically
dephosphorylated upon PTP-PEST coexpression (top panel,
lane 2). The differences in phosphotyrosine were not due to
differential recovery of CAKb as shown by stripping and rep-
robing the phosphotyrosine Western blot with a CAKb mono-
clonal antibody (Fig. 2A, middle panel). A Western blot of whole
cell lysates revealed expression of PTP-PEST in the transfected
cells (Fig. 2A, bottom panel, lane 2). To determine if CAKb
dephosphorylation was specific, whole cell lysates were West-
ern blotted for phosphotyrosine. Except for a band correspond-
ing to CAKb, the phosphotyrosine content of cellular proteins
in CAKb expressers and cells expressing both CAKb and PTP-
FIG. 1. PTP-PEST substrate traps CAKb. A, HEK 293 cells were transfected with wild type CAKb and treated with pervanadate. 500 mg of
cell lysate was first precleared with 10 mg of GST and then incubated with 5 mg of either GST (lane 1), GST/PTP-PESTWT (WT; lane 2), or
GST/PTP-PESTC231S (CS; lane 3). Bound CAKb was detected by Western blotting with a CAKb monoclonal antibody. B, HEK 293 cells were
transfected with wild type FAK and treated as in A. Bound FAK was detected by Western blotting. C, A7r5 rat smooth muscle cells were treated
with pervanadate and lysed. 500 mg of lysate was analyzed as in A and B, and bound CAKb was detected by Western blotting. For each blot, 25
mg of cell lysate was included as a positive control (A–C, lanes 4).
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PEST was similar (Fig. 2B, lanes 1 and 2). A reduction in the
phosphotyrosine content of a few cellular proteins was ob-
served, including a 68-kDa protein that is probably paxillin.
Another CAKb and PTP-PEST substrate is p130CAS, which
also becomes dephosphorylated upon expression of PTP-PEST
in HEK 293 cells (15). Two other CAKb-associated substrates
are the Nir proteins and PAP/KIAA0400 (43, 44). Nir2, the
most broadly expressed Nir family member, is ;140 kDa, and
PAP is 112 kDa. Although there are reduced phosphotyrosine
levels in this range of molecular masses in cells coexpressing
CAKb and PTP-PEST, tyrosine phosphorylation of endogenous
proteins is difficult to discern, since bands in this region of the
gel are obscured by the exogenously expressed CAKb. Further
experiments will be required to verify that additional CAKb
substrates become dephosphorylated in PTP-PEST-expressing
cells. These results demonstrate that PTP-PEST selectively
dephosphorylates cellular proteins when expressed in HEK 293
cells, suggesting that CAKb is a substrate of PTP-PEST in vivo.
To further explore the specificity of CAKb dephosphoryl-
ation, the ability of PTP-PEST to dephosphorylate FAK in vivo
was also examined. FAK or CAKb were expressed in HEK 293
cells either alone or with different amounts of PTP-PEST, and
their phosphotyrosine content was examined by immunopre-
cipitation and Western blotting. As seen in Fig. 3A, coexpres-
sion of PTP-PEST with FAK resulted in a reduction in tyrosine
phosphorylation of FAK. However, even in the presence of
relatively high levels of PTP-PEST, very substantial levels of
tyrosine-phosphorylated FAK remain (Fig. 3A, lane 4). In con-
trast, coexpression of even low levels of PTP-PEST with CAKb
virtually abolished tyrosine phosphorylation of CAKb (Fig. 3B,
lane 2). To further explore the regulation of tyrosine phospho-
rylation of FAK by PTP-PEST, the level of phosphotyrosine
present on endogenous FAK was examined. Expression of PTP-
PEST in HEK 293 induced a very modest decrease in the
phosphotyrosine content of endogenous FAK (Fig. 3C). The
expression of endogenous CAKb in HEK 293 cells was virtually
undetectable, precluding a similar analysis for CAKb (data not
shown). These results are consistent with the hypothesis that
CAKb is a specific substrate for PTP-PEST, whereas FAK is a
much weaker substrate.
PTP-PEST Targets the Major Autophosphorylation Site and
Activation Loop of CAKb—In order to determine what site(s) of
tyrosine phosphorylation of CAKb is targeted by PTP-PEST,
site-specific CAKb mutants in which tyrosines were replaced
with phenylalanine were used (34). These mutants (Y402F,
Y579F/Y580F, Y881F) and wild type CAKb were expressed in
HEK 293 cells. The cells were then either left unstimulated or
treated with pervanadate, lysed, and subjected to the sub-
strate-trapping assay. As expected, GST/PTP-PESTC231S was
able to trap wild type CAKb from pervanadate-treated cells,
while GST/PTP-PESTWT could not (Fig. 4A, compare lanes 2
and 4). Further, neither GST/PTP-PESTWT nor GST/PTP-
PESTC231S bound to CAKb from cells that were not treated
with pervanadate. GST/PTP-PESTC231S also trapped Y881F to
a similar extent as wild type CAKb (Fig. 4A, compare lanes 4
and 16). The Y402F mutant was also trapped by GST/PTP-
PESTC231S, although binding was reduced relative to wild type
or Y881F CAKb (Fig. 4A, compare lane 8 with lanes 4 and 16).
However, the Y579F/Y580F mutant was only very weakly
trapped by GST/PTP-PESTC231S (Fig. 4A, lane 12), and this
was only apparent upon overexposure of the Western blot (data
not shown). Similar levels of each CAKb variant were detected
in cell lysates (Fig. 4B); thus, these results are not due to
differential expression. These results suggest that the activa-
tion loop tyrosines are specifically targeted for dephosphoryl-
ation by CAKb.
One trivial explanation why the Y579F/Y580F mutant was
poorly trapped is that its phosphotyrosine content is lower than
FIG. 2. PTP-PEST dephosphorylates CAKb. A, CAKb was ex-
pressed in HEK 293 cells either alone (lane 1) or with wild type PTP-
PEST (lane 2). CAKb was immunoprecipitated (IP), and its phosphoty-
rosine (Ptyr) content was examined by Western blotting (Blot; top
panel). The blot was stripped and reprobed with a CAKb monoclonal
antibody (middle panel). PTP-PEST expression is shown in the Western
blot in the bottom panel. B, 25 mg of cell lysate was analyzed by Western
blotting using a phosphotyrosine antibody. The positions of molecular
weight markers are indicated at the right.
FIG. 3. Comparison of FAK and CAKb dephosphorylation in
vivo. A, FAK was expressed alone (lane 1) or cotransfected with 0.5 mg
(lane 2), 1 mg (lane 3), or 2 mg of pcDNA/PTP-PEST (lane 4). Cells were
lysed, and FAK was immunoprecipitated. The immune complexes were
Western blotted with an antibody against phosphotyrosine (ptyr; top
panel) or FAK (middle panel). Cell lysates were Western blotted using
an antibody against PTP-PEST to verify expression (bottom panel). B,
CAKb was expressed alone (lane 1) or cotransfected with 0.5 mg (lane 2),
1 mg (lane 3), or 2 mg of pcDNA/PTP-PEST (lane 4). Cells were lysed,
and CAKb was immunoprecipitated. The immune complexes were
Western blotted with an antibody against phosphotyrosine (top panel)
or CAKb (middle panel). Cell lysates were Western blotted using an
antibody against PTP-PEST to verify expression (bottom panel). C,
HEK 293 cells transfected with empty vector (lane 1) or
pcDNA/PTP-PEST (lane 2) were lysed, and endogenous FAK was im-
munoprecipitated. The immune complexes were blotted for phosphoty-
rosine (top panel) or FAK (middle panel). Lysates were blotted for
PTP-PEST to verify expression (bottom panel).
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that of the wild type protein or the other CAKb mutants from
pervanadate-treated cells. To examine this possibility, CAKb
was immunoprecipitated from pervanadate-treated lysates and
Western blotted for phosphotyrosine. Whereas similar levels of
phosphotyrosine were seen in wild type and Y881F (data not
shown), Y402F exhibited a slight decrease in its phosphoty-
rosine content relative to wild type, and Y579F/Y580F had
dramatically reduced levels of phosphotyrosine (Fig. 5A). A
CAKb Western blot shows that equal amounts of each variant
were immunoprecipitated (Fig. 5D); thus, the reduced signal on
Y579F/Y580F is really due to lower levels of phosphotyrosine.
This result could simply reflect the fact that Y579F/Y580F is
missing two sites of phosphorylation and thus is expected to be
hypophosphorylated. Alternatively, since Tyr579 and Tyr580 are
important for CAKb kinase activity, it was possible that other
sites of tyrosine phosphorylation, especially the major auto-
phosphorylation site at Tyr402, were hypophosphorylated in the
Y579F/Y580F mutant. In order to test this hypothesis, phos-
phospecific antibodies recognizing distinct CAKb phosphoty-
rosine residues were employed. CAKb immune complexes pre-
pared from lysates of pervanadate-treated HEK 293 cells were
analyzed by Western blotting. An antibody specific for phos-
phorylated Tyr402 (PY402) was used to examine phosphoryla-
tion of this site. Western blotting with PY402 revealed strong
reactivity with wild type CAKb (Fig. 5B, lane 2). This antibody
was specific, since it did not react with the Y402F mutant of
CAKb (Fig. 5B, lane 3). The Y579F/Y580F mutant did contain
dramatically reduced levels of phosphorylation on Tyr402 as
compared with wild type CAKb (Fig. 5B, compare lane 4 with
lane 2). An antibody specific for CAKb that is dually phospho-
rylated on Tyr579 and Tyr580 (PY579/580) recognized wild type
CAKb but very poorly recognized the Y579F/Y580F mutant
(Fig. 5C, lanes 2 and 4); thus, this antibody is also specific. The
PY579/580 antibody recognized the Y402F mutant to a lesser
extent than wild type CAKb (Fig. 5C, lanes 2 and 3), suggesting
that Y402F exhibits reduced phosphorylation of the activation
loop tyrosine residues. The results of these experiments under-
score the complex regulation of CAKb by tyrosine phosphoryl-
ation. The activation loop tyrosine residues must be phospho-
rylated for maximal catalytic activity of CAKb, and thus the
Y579F/Y580F mutant exhibits reduced tyrosine phosphoryla-
tion of the autophosphorylation site (Tyr402). Conversely, the
association of Src family PTKs with the autophosphorylation
site of CAKb is required for maximal phosphorylation of the
activation loop tyrosine residues, and thus the Y402F mutant
exhibits reduced tyrosine phosphorylation at these sites.
Dephosphorylation of Tyr402 and Tyr579/580 by PTP-PEST in
Vitro—In order to confirm the dephosphorylation of specific
tyrosine residues on CAKb by PTP-PEST, an in vitro phospha-
tase assay was employed. Lysates of pervanadate-treated HEK
293 cells expressing wild type CAKb were incubated with GST/
FIG. 4. PTP-PEST targets activa-
tion loop tyrosines. A, HEK 293 cells
expressing wild type CAKb (WT; lanes
1–4), Y402F CAKb (lanes 5–8), Y579F/
Y580F CAKb (lanes 9–12), or Y881F
CAKb (lanes 13–16) were treated with
pervanadate (PV: 1) or left untreated
(PV: 2). The cells were lysed and sub-
jected to substrate-trapping assays using
GST/PTP-PESTWT (WT) or GST/PTP-
PESTC231S (CS) as in Fig. 1. Bound pro-
tein was detected by Western blotting
with a monoclonal CAKb antibody. B,
Western blot of 25 mg of whole cell lysate
displaying expression levels of the CAKb
constructs.
FIG. 5. Analysis of tyrosine phosphorylation using CAKb phos-
phospecific antibodies. HEK 293 cells were transfected with either
empty vector (lane 1), wild type CAKb (lane 2), Y402F CAKb (lane 3), or
Y579F/Y580F CAKb (lane 4). Cells were treated with pervanadate and
lysed. CAKb was immunoprecipitated and blotted with a phosphotyrosine
antibody (A), a phosphospecific antibody recognizing Tyr(P)402 (B), a phos-
phospecific antibody recognizing Tyr(P)570/580 (C), or CAKb (D).
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PTP-PESTWT for various times at room temperature or on ice
for 1 h. CAKb was immunoprecipitated from the lysates and
analyzed for phosphotyrosine by Western blotting. Incubation
with the phosphatase for 5 min at room temperature resulted
in a reduction in the phosphotyrosine content of CAKb, al-
though significant levels of phosphotyrosine remained (Fig. 6A,
lane 2). Incubation for up to 20 min at room temperature did
not result in further dephosphorylation of CAKb (Fig. 6A, lane
4), and CAKb was not dephosphorylated when incubated for 20
min with GST alone (Fig. 6A, lane 5). In contrast to the result
using a phosphotyrosine antibody (Fig. 6A), the results using
phosphospecific antibodies demonstrated very dramatic reduc-
tions in the levels of phosphorylation of Tyr402 and Tyr579/580
(Fig. 6, B and C, lanes 2 and 3). A CAKb Western blot verified
that similar amounts of protein were recovered in the immune
complexes (Fig. 6D). Since little tyrosine phosphorylation of
CAKb was detected with the phosphospecific antibodies, the
phosphotyrosine seen in Fig. 6A is probably due to phosphoryl-
ation of other tyrosine residues. FAK can be phosphorylated on
at least six tyrosine residues (45, 46), and similarly CAKb is
anticipated to have other sites of tyrosine phosphorylation.
These results demonstrate that the PTP-PEST can target
Tyr402 and Tyr579/580 for dephosphorylation in vitro yet spares
other tyrosine residues within CAKb from dephosphorylation.
PTP-PEST Inhibits CAKb Kinase Activity—Phosphorylation
of Tyr579 and Tyr580 in the activation loop of CAKb enhances its
kinase activity (34). To test the possibility that PTP-PEST
could function to negatively regulate CAKb kinase activity,
HEK 293 cells overexpressing either wild type CAKb or the
Y579F/Y580F mutant were treated with pervanadate. Lysates
were then incubated with either GST alone or GST/PTP-
PESTWT to catalyze dephosphorylation of CAKb in vitro. CAKb
was then immunoprecipitated and subjected to an in vitro
kinase assay using GST-paxillinN-C3 as an exogenous sub-
strate. CAKb very effectively phosphorylates this substrate in
vitro (Fig. 7A, lane 1). As shown in Fig. 7A, CAKb kinase
activity was dramatically reduced in lysates incubated with
GST/PTP-PESTWT compared with lysates incubated with GST
alone (compare lanes 1 and 2). Further, phosphorylation of the
activation loop tyrosines was important for optimal catalytic
activity of CAKb, since Y579F/Y580F exhibited dramatically
reduced catalytic activity relative to wild type CAKb (Fig. 7A,
lane 3). Western blotting for CAKb revealed that equal
amounts of wild type and Y579F/Y580F were present in the
immune complexes (Fig. 7B, lanes 1 and 2). If PTP-PEST is
negatively regulating CAKb kinase activity by dephosphoryl-
ation of activation loop tyrosines, then the phosphatase should
have no effect on the Y579F/Y580F CAKb mutant. This was
indeed the case, since Y579F/Y580F had the same level of
kinase activity regardless of whether the lysate was incubated
with GST or GST/PTP-PESTWT (Fig. 7A, compare lanes 3 and
4). Interestingly, when wild type CAKb was incubated in the
presence of GST/PTP-PESTWT, its kinase activity was reduced
to almost the level of activity exhibited by the Y579F/Y580F
mutant (Fig. 7A, compare lanes 2 and 3). This result supports
the hypothesis that PTP-PEST is targeting activation loop ty-
rosines and that dephosphorylation of CAKb by PTP-PEST
impairs catalytic activity of the kinase. Unlike CAKb, PTP-
PEST had little or no effect on the kinase activity of FAK.
Similar catalytic activities were observed following incubation
with GST alone and with GST/PTP-PESTWT (Fig. 7C, compare
lanes 1 and 2). This finding demonstrates the substrate speci-
ficity of PTP-PEST, since it inhibited the catalytic activity of
CAKb in vitro but had no effect on the highly related tyrosine
kinase, FAK.
FIG. 6. Dephosphorylation of Tyr402 and Tyr579/580 by PTP-
PEST in vitro. 1 mg of lysate from pervanadate-treated HEK 293 cells
expressing CAKb was incubated with 4 mg of GST/PTP-PESTWT for 5
min (lane 2), 10 min (lane 3), or 20 min at room temperature (lane 4). As
controls, lysate was unexposed to phosphatase (lane 1) or incubated
with GST for 20 min at room temperature (lane 5). CAKb was immu-
noprecipitated from 300-mg aliquots, and the immune complexes were
Western blotted with an anti-phosphotyrosine antibody (A), the phos-
phospecific PY402 antibody (B), the phosphospecific PY579/580 anti-
body (C), or a CAKb antibody (D). As controls for antibody specificity,
CAKb immune complexes from mock-transfected HEK 293 cells (lane 6)
or cells expressing wild type CAKb (lane 7), Y402F (lane 8), or Y579/
580F (lane 9) were included.
FIG. 7. PTP-PEST inhibits CAKb kinase activity. A, 300 mg of
pervanadate-treated lysate of HEK 293 cells expressing either wild type
CAKb (lanes 1 and 2) or Y579F/Y580F CAKb (lanes 3 and 4) were
incubated with either 2 mg of GST alone (lanes 1 and 3) or GST/PTP-
PESTWT (lanes 2 and 4). CAKb was immunoprecipitated and subjected
to an in vitro kinase assay using GST-paxillinN-C3 as a substrate. The
reaction was terminated and analyzed by SDS-PAGE and autoradiog-
raphy. The region of the autoradiograph containing the recombinant
paxillin is shown. B, CAKb was immunoprecipitated as in A. Immune
complexes were subjected to SDS-PAGE and Western blotting with a
CAKb monoclonal antibody. C, HEK 293 cell lysates expressing wild type
FAK were incubated with GST or GST/PTP-PESTWT, and FAK was im-
munoprecipitated and analyzed in an in vitro kinase assay as in A. D,
HEK 293 cells were transfected with either wild type CAKb (lane 1), FAK
(lane 3), CAKb and wild type PTP-PEST (lane 2), or FAK and wild type
PTP-PEST (lane 4). CAKb (lanes 1 and 2) and FAK (lanes 3 and 4) were
immunoprecipitated and subjected to kinase assays as in A and C.
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PTP-PEST was also able to inhibit the kinase activity of
CAKb in vivo when the two were coexpressed in HEK 293 cells.
The catalytic activity of CAKb was measured by immunopre-
cipitating the kinase from cell lysates and incubating the im-
mune complex in an in vitro kinase assay. The catalytic activity
of CAKb immunoprecipitated from cells coexpressing PTP-
PEST was dramatically reduced relative to the catalytic activ-
ity of CAKb when expressed alone (Fig. 7D, compare lanes 1
and 2). In contrast, the catalytic activity of FAK immunopre-
cipitated from cells coexpressing PTP-PEST was the same as
the activity of FAK expressed alone (Fig. 7D, compare lanes 3
and 4). Thus, PTP-PEST was unable to inhibit FAK kinase
activity in vivo. These data support the substrate trapping data
and suggest that PTP-PEST prefers CAKb to FAK as a sub-
strate. Furthermore, they suggest that PTP-PEST can directly
regulate the catalytic activity of CAKb by dephosphorylation of
activation loop tyrosine residues.
PTP-PEST Negatively Regulates CAKb-dependent Tyrosine
Phosphorylation in Vivo—PTP-PEST is able to bind and de-
phosphorylate paxillin and p130CAS (13, 15). Since paxillin and
p130CAS are also binding partners of CAKb, it seemed plausible
that either of these proteins might serve as a scaffold to bring
PTP-PEST into the proximity of CAKb to allow dephosphoryl-
ation to occur. In order to address this, CAKb was expressed in
HEK 293 cells either alone or in combination with wild type
PTP-PEST or deletion mutants of PTP-PEST (D367–400 and
D297–493), shown previously to be unable to bind paxillin (15),
or a PTP-PEST mutant (P337A PTP-PEST) that is unable to
bind p130CAS (13). CAKb was immunoprecipitated from cell
lysates and Western blotted for phosphotyrosine. As already
shown in Figs. 2A and 3B, coexpression with wild type PTP-
PEST induced a complete loss of phosphotyrosine on CAKb
(Fig. 8A, lane 2, top panel). Both deletion mutants and the
P337A mutant were able to induce CAKb dephosphorylation to
the same extent as wild type PTP-PEST (Fig. 8A, lanes 3–5, top
panel). The blot was stripped and reprobed with a CAKb mono-
clonal antibody to show that equal levels of protein were im-
munoprecipitated (Fig. 8A, bottom panel). This result suggests
that the association of PTP-PEST with neither paxillin nor
p130CAS is necessary for dephosphorylation of CAKb by
PTP-PEST.
Expression of CAKb in chick embryo fibroblasts results in
enhanced phosphorylation of paxillin (47). Similarly, paxillin
becomes hyperphosphorylated when CAKb is overexpressed in
HEK 293 cells (Fig. 8B, compare lanes 1 and 3). Coexpression
of PTP-PEST with CAKb results in a reduction in paxillin
phosphotyrosine levels (Fig. 8B, compare lanes 3 and 4). This
could be the result of PTP-PEST inhibiting phosphorylation of
paxillin by negatively regulating CAKb kinase activity. Alter-
natively, PTP-PEST could also be dephosphorylating paxillin
itself, since paxillin was shown to be a substrate for PTP-PEST
(15). The PTP-PEST deletion mutants deficient in paxillin
binding were used to address this question. Paxillin binding is
essential for the direct dephosphorylation of paxillin by PTP-
PEST (15). As shown in Fig. 8A, paxillin binding is completely
dispensable for dephosphorylation of CAKb by PTP-PEST. Ei-
ther D367–400 or D297–493 PTP-PEST mutants were coex-
pressed with CAKb in HEK 293 cells. Paxillin was then immu-
noprecipitated, and its phosphotyrosine content was examined
by Western blotting. Both D367–400 and D297–493 mutants
were able to reduce paxillin phosphotyrosine levels compared
with cells expressing CAKb alone (Fig. 8B, compare lanes 5 and
6 with lane 3). Since both mutants fail to directly dephospho-
rylate paxillin (15), this result implies that PTP-PEST is indi-
rectly reducing tyrosine phosphorylation of paxillin by inhibit-
ing CAKb. However, both deletion mutants were unable to
reduce paxillin phosphotyrosine levels to the same extent as
wild type PTP-PEST (Fig. 8B, compare lanes 5 and 6 with lane
4). Whole cell lysates were Western blotted with the polyclonal
PTP-PEST antiserum to demonstrate that differences in levels
of tyrosine phosphorylation of paxillin were not due to differ-
ences in expression levels of wild type PTP-PEST and the
various mutants (Fig. 8C). These results suggest that PTP-
PEST also acts to directly dephosphorylate paxillin. Therefore,
PTP-PEST is able to negatively regulate a signal sent by CAKb
in vivo by targeting both the kinase and its substrate for
dephosphorylation.
Subcellular Localization of Endogenous PTP-PEST and
CAKb—FAK is unlikely to be a major target for PTP-PEST in
vivo, since FAK is localized in focal adhesions and PTP-PEST is
found in the cytoplasm (37, 48). To determine if PTP-PEST and
CAKb reside in the same cellular compartment, their subcel-
lular localization was examined by immunofluorescence in the
GN4 and A7r5 cell lines, which express both of these proteins
FIG. 8. PTP-PEST negatively regulates CAKb-dependent tyrosine phosphorylation in vivo. A, CAKb was expressed in HEK 293 cells
either alone (lane 1) or with wild type PTP-PEST (lane 2), D367–400 (lane 3), D297–493 (lane 4), or P337A PTP-PEST (lane 5). CAKb was
immunoprecipitated, and its phosphotyrosine content was examined by Western blotting (top panel). The blot was stripped and reprobed with a
CAKb monoclonal antibody (bottom panel). B, paxillin was immunoprecipitated from HEK 293 cell lysate (lane 1) or from HEK 293 cell lysates
expressing PTP-PEST (lane 2), CAKb (lane 3), CAKb and PTP-PEST (lane 4), CAKb and D367–400 (lane 5), CAKb and D297–493 (lane 6), or CAKb
and P337A PTP-PEST (lane 7). The immune complexes were analyzed by Western blotting for phosphotyrosine (top panel). The blot was stripped
and reprobed with a paxillin monoclonal antibody (bottom panel). C, 25 mg of whole cell lysates were examined for PTP-PEST expression by
Western blotting with a polyclonal antiserum.
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endogenously. In both cell types, immunofluorescent staining
for both PTP-PEST and CAKb was relatively nondescript. Each
protein was located within the cytoplasm of the cells, and the
staining appeared particulate (Fig. 9). As a control, the primary
antibodies were omitted, resulting in very dim background
fluorescence (Fig. 9, A and B). This result confirms previous
findings that PTP-PEST and CAKb are localized in the cyto-
plasm of cells (47–49) and supports the contention that CAKb
may be a physiological substrate for PTP-PEST, since both are
found in a similar cellular compartment.
DISCUSSION
In this study, we have demonstrated the direct regulation of
the PTK CAKb by PTP-PEST. CAKb is substrate-trapped by a
catalytically inactive PTP-PEST mutant and is dephosphoryl-
ated in vivo when coexpressed with PTP-PEST. PTP-PEST
targets tyrosine residues 579 and 580 in the activation loop of
CAKb for dephosphorylation. As a result, PTP-PEST decreases
CAKb kinase activity both in vitro and in vivo. This inhibition
of CAKb kinase activity results in the reduced ability of CAKb
to phosphorylate paxillin in vivo. In addition, PTP-PEST tar-
gets tyrosine residue 402 for dephosphorylation. Loss of phos-
phorylation at this site will prevent Src family kinases from
binding to CAKb, which in turn will result in reduced tyrosine
phosphorylation of CAKb and other downstream substrates in
the pathway. Perhaps as interesting, the results also demon-
strate that PTPs can exhibit very strong specificity for sub-
strates, since PTP-PEST appears to strongly prefer CAKb as a
substrate to its highly homologous relative, FAK.
There are several observations regarding tyrosine phospho-
rylation of CAKb that merit further discussion. First, when
PTP-PEST is coexpressed with CAKb, a complete loss of phos-
photyrosine on CAKb is observed (Fig. 2A, top panel). Since
PTP-PEST appears to target Tyr402, Tyr579, Tyr580, the com-
plete loss of phosphotyrosine on CAKb is intriguing. Perhaps
these three sites are the only residues phosphorylated when
CAKb is exogenously expressed in cells. If other tyrosine resi-
dues are phosphorylated upon CAKb expression, how are these
sites dephosphorylated upon PTP-PEST overexpression? One
possible explanation is that by targeting the activation loop,
PTP-PEST turns off CAKb kinase activity, and by directly
dephosphorylating Tyr402 the Src family kinase binding site is
removed. As a result, Src can no longer bind CAKb and
transphosphorylate other tyrosine residues, such as Tyr881, on
CAKb. Second, the observed pattern of tyrosine phosphoryla-
tion of CAKb mutants following pervanadate treatment differs
from the published pattern of phosphorylation from untreated
cells (34). When expressed in HEK 293(T) cells, the Y402F
mutant has been reported to be virtually devoid of phosphoty-
rosine, and the Y579F/Y580F mutant exhibits levels of phos-
photyrosine dramatically lower than wild type CAKb. In fact,
we find similar results in experiments in which the cells are not
pervanadate-treated (data not shown). These findings suggest
that tyrosine 402 is the major site of tyrosine phosphorylation
and/or a prerequisite site of phosphorylation for the phospho-
rylation of additional tyrosine residues. The observation that
pervanadate treatment induces tyrosine phosphorylation of the
Y402F mutant suggests that the SH2 domain-mediated asso-
ciation of Src with CAKb may not be absolutely required for
phosphorylation of additional tyrosine residues in CAKb. This
result suggests that there is a second mechanism for tyrosine
phosphorylation of CAKb, although this is probably a minor
mechanism of phosphorylation, since it only becomes evident
following inhibition of PTPs with pervanadate. However, the
SH2-mediated interaction between Src and CAKb may be nec-
essary for optimal phosphorylation of the activation loop, since
Y402F exhibits lower levels of phosphotyrosine on residues
579/580 than wild type CAKb, even from pervanadate-treated
cells (34) (Fig. 5B).
PTP-PEST is not the only phosphatase reported to associate
with CAKb. It was recently reported that SHP-1 binds consti-
tutively to CAKb (50). The data suggest that SHP-1 is involved
in dephosphorylation of Tyr402, the major autophosphorylation
and Src-SH2 binding site. Unlike PTP-PEST, SHP-1 had no
effect on CAKb kinase activity. SHP-2, another SH2 domain-
containing protein-tyrosine phosphatase, was also recently re-
ported to constitutively associate with CAKb (51). SHP-2 bind-
ing to CAKb was shown to be independent of SHP-2 SH2
domains. Further, CAKb was dephosphorylated in vivo upon
expression of a SHP-2 mutant with enhanced phosphatase
activity that lacks its two N-terminal SH2 domains. Additional
studies are required to establish which site(s) are targeted by
SHP-2 and whether SHP-2 can regulate CAKb kinase activity.
One intriguing possibility is that SHP-1 and SHP-2 function
cooperatively with PTP-PEST in down-regulating CAKb sig-
naling. According to this model, PTP-PEST may be responsible
for turning off CAKb kinase activity by dephosphorylation of
activation loop residues, and SHP-1 or SHP-2 may be respon-
sible for inhibiting the assembly of the Src-CAKb complex by
dephosphorylating the Src SH2 domain binding site.
Surprisingly, PTP-PEST substrate trapped CAKb much bet-
ter than FAK. Small amounts of FAK could sometimes be found
in association with the PTP-PEST substrate-trapping mutant,
but it was always much less in comparison with CAKb.2 This
does not rule out the possibility that FAK may be a substrate
for PTP-PEST. For example, paxillin was unable to be sub-
strate-trapped but nevertheless appears to be a substrate for
PTP-PEST, since it directly binds PTP-PEST and becomes
dephosphorylated in vivo upon overexpression of wild type
PTP-PEST (15). Despite the failure of PTP-PEST to efficiently
substrate-trap FAK, there is some evidence suggesting that
PTP-PEST could regulate FAK dephosphorylation. First, PTP-
PEST activity was coimmunoprecipitated with FAK from ly-
sates of chicken embryo fibroblasts (36). Second, FAK was
hyperphosphorylated in fibroblasts where PTP-PEST was re-
moved by gene targeting (29). However, PTP-PEST and FAK
have never been colocalized in cells. PTP-PEST is localized
diffusely throughout the cytoplasm or at the membrane periph-
ery upon cell adhesion to fibronectin (29), whereas FAK is
predominately localized in focal adhesions (37). Clearly, fur-
ther experimentation is required to define the role of PTP-
FIG. 9. Localization of endogenous PTP-PEST and CAKb in
GN4 and A7r5 cells. GN4 cells (A, C, and E) and A7r5 cells (B, D, and
F) were fixed, permeabilized, and incubated with a PTP-PEST mono-
clonal antibody (C and D) or a CAKb monoclonal antibody (E and F).
The primary antibodies were detected with secondary rabbit anti-
mouse and tertiary donkey anti-rabbit conjugated to fluorescein. The
primary antibody was omitted in control slides (A and B). The GN4 cells
were observed with a 3 63 objective, and the A7r5 cells were observed
with a 3 40 objective.
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PEST in dephosphorylating FAK. Interestingly, FAK has recently
been shown to associate with several other tyrosine phosphatases
including PTEN/MMAC1 (52, 53), PTP1B (54–56), and SHP-2 (57,
58). It is possible that one or more of these phosphatases is respon-
sible for regulating FAK dephosphorylation.
The observation that CAKb can be substrate-trapped by
PTP-PEST better than FAK raises the interesting question of
substrate specificity, since CAKb and FAK are highly homolo-
gous, sharing 45% overall sequence identity and 60% identity
in the catalytic domain. As stated previously, they share sev-
eral conserved tyrosine residues, including two tyrosines in the
catalytic domain. Why then does PTP-PEST so strongly prefer
CAKb? One reason may be a slight difference in amino acid
sequence surrounding the adjacent tyrosine residues. In the
activation loop, the CAKb sequence is 575EDEDpYpYKAS583
(where pY represents phosphotyrosine), while the equivalent
FAK sequence is 572EDSTpYpYKAS580. It may be that the
difference in the sequences immediately upstream of the phos-
phorylated tyrosine residues is the reason that PTP-PEST pre-
fers CAKb as a substrate. This is probably the case, since
several reports have suggested that aspartic acid and glutamic
acid within the first 5 residues N-terminal to the phosphoryl-
ated tyrosine residues increases the binding affinity of several
phosphatases for their substrates and increase catalysis of the
substrate (59–61). In addition, the crystal structure of another
cytoplasmic tyrosine phosphatase, PTP1B, complexed with a
high affinity substrate has been determined (62). The crystal
structure suggests that substrate specificity is conferred by the
interaction of basic residues on the surface of the phosphatase
with acidic residues of the peptide that lie to the N-terminal
side of the phosphorylated tyrosine residue.
Paxillin is phosphorylated upon overexpression of CAKb in
HEK 293 cells (Fig. 8) and is presumably a downstream effector
of CAKb signaling. Both paxillin and CAKb are substrates for
PTP-PEST, suggesting a model whereby PTP-PEST regulates
this pathway at two distinct points (Fig. 10). First, PTP-PEST
is able to directly bind and dephosphorylate paxillin. Second,
PTP-PEST dephosphorylates activation loop tyrosine residues
on CAKb, rendering the kinase catalytically inactive, and fur-
ther targets the major autophosphorylation and Src kinase
binding site of CAKb. Inhibition of the kinase activity of CAKb
and blocking recruitment of Src kinases, in turn, prevents the
CAKb-Src kinase complex from phosphorylating its down-
stream substrate, paxillin. Perhaps regulation at these two
distinct points is required for complete inactivation of this
signal. Alternatively, there may be additional, independent
mechanisms regulating targeting of these two PTP-PEST sub-
strates for dephosphorylation. In this case, CAKb signaling
could be inhibited by dephosphorylation of the kinase. Alter-
natively, one branch of the CAKb signaling cascade could be
blocked by dephosphorylation of paxillin, allowing other CAKb-
dependent signals to be propagated. This targeting of distinct
members of this signaling pathway under specific conditions
might increase the versatility of signals transmitted.
The discovery that PTP-PEST can regulate the catalytic
activity of CAKb and phosphorylation of CAKb substrates pro-
vides important new insight into signaling via this pathway.
The efficient transmission of downstream signals might re-
quire the regulation of both the PTK and the PTP, which could
involve changes in the catalytic activity of these enzymes
and/or alterations in protein-protein interactions. There is
clearly considerable work to be done to unravel the complex
interplay between these two enzymes and determine how their
activities might be coordinated to allow the propagation of
signals.
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